Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02155595 · ClinicalTrials.gov registry record
Pathogenesis of Atypical Femur Fractures on Long Term Bisphosphonate Therapy
A clinical trial, sponsored by Henry Ford Health System.
- Completed
- Registry status
- 738
- Enrollment target
NCT02155595: Completed study, sponsored by Henry Ford Health System.
NCT02155595 is a clinical trial that has completed, run by Henry Ford Health System. The registered enrollment target is 738 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02155595 has completed, sponsored by Henry Ford Health System.
- COMPLETED
- Registry status
- 738 participants
- Enrollment target
Study Summary
The purpose of this protocol is to determine the risk of atypical femoral shaft (thigh bone) fractures after long term fracture prevention therapy with a class of drugs called "bisphosphonates", colloquially referred to as Alendronate, risedronate, Ibandronate, and Zoledronate. In addition, the study is designed to find out which patient is most likely to develop this potential life changing complication and why. Finally, the results of this study will help clinicians to better understand the reason and thus tailor patient specific treatments…i.e., "the right treatment for the right patient for right duration."
Primary Outcome
Determine the prevalence of PBD and/or Atypical Femoral Fractures (AFF) in patients with post-menopausal or glucocorticoid related osteoporosis, either treated with bisphosphonate (BP) for more than 2 years or never treated with a BP
Interventions
- OTHER 500 without BP treatment
- OTHER 500 with BP treatment
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 738 participants |
| Start Date | 2014-05 |
| Est. Completion | 2018-08-31 |
What the finished NCT02155595 record still lists
NCT02155595 is an observational study that tracks outcomes without assigning an intervention. The registered 738 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 2 interventions - of which 500 without BP treatment is the first listed.
NCT02155595 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02155595 about?
NCT02155595 is a clinical study titled "Pathogenesis of Atypical Femur Fractures on Long Term Bisphosphonate Therapy". The purpose of this protocol is to determine the risk of atypical femoral shaft (thigh bone) fractures after long term fracture prevention therapy with a class of drugs called "bisphosphonates", colloquially referred to as Alendronate, risedronate, Ibandronate, and Zoledronate. In addition, the stu...
What is the current status of trial NCT02155595?
This trial is currently completed. The enrollment target is 738 participants. The study started on 2014-05. Estimated completion is 2018-08-31.
What interventions are being tested in trial NCT02155595?
The interventions under investigation include: 500 without BP treatment (OTHER), 500 with BP treatment (OTHER).
Who is sponsoring clinical trial NCT02155595?
This trial is sponsored by Henry Ford Health System, which has 234 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03723928 · 739 participants · NA
S1703 Serum Tumor Marker Directed Disease Monitoring in Patients With Hormone Receptor Positive Her2 Negative Metastatic Breast Cancer
- NCT03963622 · 740 participants · NA
Careful Ventilation in Acute Respiratory Distress Syndrome (COVID-19 and Non-COVID-19)
- NCT04074135 · 740 participants · Phase 2
Natural History and Management of Von Hippel-Lindau (VHL) Associated Pancreatic Neuroendocrine Tumors
- NCT05215340 · 740 participants · Phase 3
Study of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects With Advanced or Metastatic NSCLC Without Actionable Genomic Alterations
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia